Vemurafenib Terminated Phase 2 Trials for Malignant Melanoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01586195Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
NCT02050321A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma